Lotus, NRx and Alvogen team up for S-TRBD therapy NRX-101

06 Jun 2023
www.pharmaceutical-technology.com
Cell TherapyLicense out/in
Lotus, NRx and Alvogen team up for S-TRBD therapy NRX-101
Preview
Source: Pharmaceutical Technology
NRX-101 will be used for suicidal treatment-resistant bipolar depression. Credit: Lotus.
Lotus Pharmaceuticals, NRx Pharmaceuticals and Alvogen have entered a global collaboration deal to develop and commercialise NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD).
Lotus will purchase global rights for NRX-101 and handle the commercialisation activities of the product in markets outside the US.
Recommended Reports
Lotus, NRx and Alvogen team up for S-TRBD therapy NRX-101
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - CYMS-101 in Relapsing Remitting Multiple Sclerosis (RRMS) GlobalData
Lotus, NRx and Alvogen team up for S-TRBD therapy NRX-101
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Gene-Modified Cell Therapy for Hypophosphatasia GlobalData
View allCompanies IntelligenceLotus Pharmaceuticals IncNRX Pharmaceuticals IncAlvogen IncView all
The company will collaborate with AlvogenAlvogen to commercialise NRX-101 in the US through the Almatica label, the CNS-focused division of AlvogenAlvogen.
Lotus and Alvogen will also provide funding for the next registrational trial to support NRX-101’s approval.
They will have a right to negotiate for new indications for NRX-101 outside the field of suicidal bipolar depression and/or potential new products comprising D-cycloserine along with an antidepressant/antipsychotic.
NRx Pharmaceuticals will receive an initial payment of $10m on obtaining successful findings from the ongoing Phase IIb/III clinical trial and on completion of a Type B meeting with the US Food and Drug Administration (FDA).
The company will receive a further $5m on gaining US FDA approval for NRX-101, and $330m milestone payments on reaching net sales targets.
It will also be eligible for a royalty on net sales between 12% and 16%, contingent upon meeting sales thresholds in the US market, and for payments based on the success of the product in other global markets.
NRx Pharmaceuticals CEO Stephan Willard stated: “This collaboration can accelerate the delivery of NRX-101 to patients grappling with suicidal bipolar depression who desperately need better treatment alternatives.
“This global partnership significantly minimises the need for future capital raises for NRX-101 development and commercialisation.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.